WST
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc historical holders
total: 4
Bill & Melinda Gates Foundation Trust West Pharmaceutical Services Inc transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2025 Q1
- Held for:
- 5 quarters
- Latest activity:
- 2025 Q1
Bill Gates has been an institutional investor in West Pharmaceutical Services Inc (WST) since 2025 Q1. According to 2026 Q1 report, Bill Gates holds 444,500 shares with a market value of roughly $111.41M representing 0.35% of their equity portfolio. The fund/company first acquired WST in 2025 Q1, initially purchasing 444,500 shares.
Does Bill Gates still hold WST?
Yes, Bill Gates continues to hold West Pharmaceutical Services Inc (WST). According to their 2026 Q1 report, they maintain a position of 444,500 shares valued at approximately $111.41M, representing 0.35% of their equity portfolio.
When did Bill Gates first invest in WST?
Bill Gates first invested in West Pharmaceutical Services Inc (WST) in 2025 Q1 at the reported quarter-end price of $223.88 per share, acquiring 444,500 shares in their initial purchase.
What is Bill Gates's average cost basis for WST?
Based on historical transaction data, Bill Gates's estimated cost basis for West Pharmaceutical Services Inc (WST) is approximately $223.88 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $223.88
WST transactions history by Bill & Melinda Gates Foundation Trust
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.24%
|
444,500
|
$223.88
|
$99,514,660
|
new
|
+0.24%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.